Reneo Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Onkure Therapeutics

22/03/2024 12:49

* Reneo Pharmaceuticals Inc  RPHM.OQ   RPHM.O  is expected
to show
no change in quarterly revenue when it reports  results on March
25 (estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Reneo Pharmaceuticals
Inc is
for a loss of 58 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 4
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Reneo
Pharmaceuticals Inc is $1.48​, below​ its last closing price
of $1.69. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.57       -0.57      -0.57     Met     0.3
 Jun. 30 2023  -0.50       -0.52      -0.65     Missed  -25.8
 Mar. 31 2023  -0.59       -0.60      -0.60     Met     0.7​
 Dec. 31 2022              -0.60      -0.56     Beat    6.8
 ​​Sep.        -0.57       -0.57      -0.53     Beat    7.3
 30 2022                                                
 Jun. 30 2022  -0.58       -0.58      -0.50     Beat    14.1​
 Mar. 31 2022  -0.52       -0.54      -0.53     Beat    2.5
 Dec. 31 2021  -0.56       -0.57      -0.43     Beat    24.6
 This summary was machine generated March 22 at 12:49 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)